Valeant Pharmaceuticals International Inc , Canada's largest listed drugmaker, swung to a quarterly profit driven by the acquisition of contact lens maker Bausch & Lomb Holdings Inc. Valeant's net income attributable to the company was $123.8 million, or 36 cents per share, for the fourth quarter ended Dec. 31. The company reported a loss of $89.1 million, or 29 cents per share, a year earlier.
Help employers find you! Check out all the jobs and post your resume.
